Use of canagliflozin in preparation of antitumor drug
AssigneeZhejiang University
InventorsBo Yang, Qiaojun He, Ling Ding
Life of this patent
Estimating the term…
Abstract
The present invention provides a use of canagliflozin in preparation of an antitumor drug, especially in preparation of a drug for treating solid tumors. It has been proven through researches that canagliflozin has a significant down-regulation effect on immune checkpoint protein PD-L1 in various tumor cells and can effectively enhance the killing effect of T cells on tumor cells in a co-incubation model of T cells and tumor cells, thereby broadening a clinical application scope of the chemical drug canagliflozin in tumor immunotherapy. The present invention provides a new medical use of canagliflozin, and also provides new approaches and potential targets for the development of small molecular drugs based on PD-L1.
Claims3
A process for treating a tumor, comprising administrating a composition into a subject suffering from a tumor,
- wherein the composition consists of canagliflozin and a pharmaceutically acceptable excipient, and the canagliflozin is (1S)-1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol, with a molecular formula of and a molecular C24H25FO5S weight of 444.516;
- wherein the tumor is non-small cell lung cancer and osteosarcoma.
Dependencies are inferred from the claim text.